|Bid||55.90 x 100|
|Ask||56.09 x 100|
|Day's Range||55.85 - 56.86|
|52 Week Range||46.01 - 77.12|
|PE Ratio (TTM)||19.42|
|Earnings Date||Jul 26, 2017 - Jul 31, 2017|
|Dividend & Yield||1.56 (2.75%)|
|1y Target Est||57.14|
Cancer drugs (oncology business) account for nearly 60% of Bristol-Myers Squibb's valuation, according to our estimates. Empirically and fundamentally speaking, the stock’s performance is highly tied to clinical trial results and the uptake of the company’s new cancer drugs.
Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.
Some class-action plaintiffs will have to find less-friendly courts for their lawsuits.